OTCMKTS:EMMA

Emmaus Life Sciences (EMMA) Stock Price, News & Analysis

Emmaus Life Sciences logo
$0.02 0.00 (0.00%)
As of 09:56 AM Eastern

About Emmaus Life Sciences Stock (OTCMKTS:EMMA)

Advanced

Key Stats

Today's Range
$0.01
▼
$0.02
50-Day Range
$0.02
▼
$0.07
52-Week Range
$0.01
▼
$0.09
Volume
150,110 shs
Average Volume
100,139 shs
Market Capitalization
$1.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Emmaus Life Sciences is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly sickle cell disease. Its main product, Endari, is an oral powder formulation of L-glutamine approved in the United States to reduce acute complications of sickle cell disease in adults and children aged 5 years and older.

The U.S. Food and Drug Administration approved Endari in 2017. Emmaus has also pursued development and commercialization opportunities for its products in markets outside the United States.

AI Generated. May Contain Errors.

Emmaus Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

EMMA MarketRank™: 
0.346053891395 of 5 stars

Emmaus Life Sciences scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Emmaus Life Sciences.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Emmaus Life Sciences is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Emmaus Life Sciences is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.02% of the float of Emmaus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Emmaus Life Sciences has a short interest ratio ("days to cover") of 0.38, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Emmaus Life Sciences has recently increased by 229.23%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Emmaus Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Emmaus Life Sciences does not have a long track record of dividend growth.

  • News Sentiment

    Emmaus Life Sciences has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Emmaus Life Sciences this week, compared to 0 articles on an average week.
  • Search Interest

    2 people have searched for EMMA on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Emmaus Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    35.00% of the stock of Emmaus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    7.42% of the stock of Emmaus Life Sciences is held by institutions.

  • Read more about Emmaus Life Sciences' insider trading history.
Receive EMMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EMMA Stock News Headlines

Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences Reports Delay in Quarterly Filing
Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
Emmaus Life Sciences Reports Annual Financial Results
See More Headlines

EMMA Stock Analysis - Frequently Asked Questions

Emmaus Life Sciences' stock was trading at $0.0130 at the beginning of 2026. Since then, EMMA stock has increased by 76.9% and is now trading at $0.0230.

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) issued its earnings results on Friday, August, 14th. The company reported $0.02 earnings per share for the quarter. The firm earned $6.32 million during the quarter.

Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Tesla (TSLA), Bloom Energy (BE), CVS Health (CVS), Anavex Life Sciences (AVXL), FuelCell Energy (FCEL), Cassava Sciences (FLNA) and Jazz Pharmaceuticals (JAZZ).

Company Calendar

Last Earnings
8/14/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:EMMA
CIK
822370
Employees
33
Year Founded
2000

Profitability

EPS (Trailing Twelve Months)
($0.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.49 million
Net Margins
-38.78%
Pretax Margin
-34.93%
Return on Equity
N/A
Return on Assets
-31.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.09
Quick Ratio
0.07

Sales & Book Value

Annual Sales
$12.45 million
Price / Sales
0.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.91) per share
Price / Book
-0.03

Miscellaneous

Outstanding Shares
70,190,000
Free Float
45,622,000
Market Cap
$1.61 million
Optionable
Not Optionable
Beta
11.25

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (OTCMKTS:EMMA) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners